High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia

• Published in: Dermatology and therapy Vol. 7; no. 4; pp. 525 - 533
• Main Authors: See, Jo-Ann, Gebauer, Kurt, Wu, Jason K., Manoharan, Shobhan, Kerrouche, Nabil, Sullivan, John
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.12.2017; Springer Nature B.V
• Subjects: Dermatology; Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT02674048; Observational studies; Oral and Maxillofacial Surgery; Original Research; Patient satisfaction; Photodynamic therapy; Plastic Surgery; Quality of Life Research; Actinic keratosis; Observational study; Australia; Daylight-activated photodynamic therapy; Methyl aminolevulinate cream
• ISSN: 2193-8210; 2190-9172
• DOI: 10.1007/s13555-017-0199-9

Introduction Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK. Methods A multicenter, prospective, observational study was conducted in Australia in patients receiving a single treatment of MAL DL-PDT for mild to moderate AK. Efficacy was assessed 3 months after treatment by investigator-assessed improvement and patient- and physician-completed satisfaction questionnaires. Adverse events were recorded throughout the study. Results Overall, 81 patients were enrolled of mean age 62.7 years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8 years). Most had multiple lesions (82.7% had >10 lesions) of predominantly grade I (75.3%). At 3 months after treatment, almost half the patients (46.8%) required no further treatment. The proportions of patients and physicians satisfied to very satisfied with the MAL DL-PDT treatment were 79.7% and 83.3%, respectively. After receiving the treatment, 74.1% of patients indicated via the questionnaire that they were not bothered at all by the pain. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%). Conclusions In clinical practice in Australia, the use of MAL DL-PDT in treating multiple mild to moderate non-hyperkeratotic AK of the face and/or scalp results in high levels of patient and physician satisfaction reflecting the good efficacy and tolerability of this almost painless, convenient procedure. Trial Registration ClinicalTrials.gov identifier, NCT02674048. Funding Galderma R&D.